Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price objective lifted by analysts at BMO Capital Markets from $15.00 to $18.00 in a research note issued on Wednesday, November 8th. The firm presently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential downside of 4.91% from the stock’s previous close.
HALO has been the topic of a number of other reports. Piper Jaffray Companies upped their price target on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, October 16th. Zacks Investment Research cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 6th. Deutsche Bank AG upped their price target on shares of Halozyme Therapeutics to $20.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Canaccord Genuity set a $16.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 26th. Finally, Jefferies Group LLC restated an “underperform” rating and issued a $7.00 price target (up from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $17.75.
Halozyme Therapeutics (NASDAQ:HALO) traded up $0.23 during mid-day trading on Wednesday, reaching $18.93. 466,881 shares of the company’s stock were exchanged, compared to its average volume of 1,415,244. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01. Halozyme Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $19.37.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The firm had revenue of $63.73 million for the quarter, compared to the consensus estimate of $58.95 million. During the same quarter last year, the firm earned ($0.23) EPS. The company’s revenue was up 100.1% on a year-over-year basis. analysts anticipate that Halozyme Therapeutics will post 0.15 EPS for the current fiscal year.
WARNING: “Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target Increased to $18.00 by Analysts at BMO Capital Markets” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/halozyme-therapeutics-inc-halo-pt-raised-to-18-00/1767390.html.
A number of large investors have recently added to or reduced their stakes in HALO. Karp Capital Management Corp purchased a new stake in Halozyme Therapeutics in the first quarter worth about $188,000. Parametric Portfolio Associates LLC lifted its stake in Halozyme Therapeutics by 37.2% in the first quarter. Parametric Portfolio Associates LLC now owns 52,784 shares of the biopharmaceutical company’s stock worth $684,000 after acquiring an additional 14,308 shares during the period. Principal Financial Group Inc. lifted its stake in Halozyme Therapeutics by 2.8% in the first quarter. Principal Financial Group Inc. now owns 20,602 shares of the biopharmaceutical company’s stock worth $267,000 after acquiring an additional 558 shares during the period. Vanguard Group Inc. lifted its stake in Halozyme Therapeutics by 3.7% in the first quarter. Vanguard Group Inc. now owns 8,763,558 shares of the biopharmaceutical company’s stock worth $113,576,000 after acquiring an additional 311,215 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Halozyme Therapeutics by 6.4% in the first quarter. Geode Capital Management LLC now owns 962,500 shares of the biopharmaceutical company’s stock worth $12,473,000 after acquiring an additional 58,215 shares during the period. 83.12% of the stock is owned by institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with our FREE daily email newsletter.